**Author Information** An event is serious (based on the ICH definition) when the patient outcome is:\* death\* life-threatening\* hospitalisation\* disability\* congenital anomaly\* other medically important event

A 5-year-old boy developed neutropenic fever, respiratory syncytial virus pneumonitis and acute respiratory distress syndrome (ARDS) following treatment with cyclophosphamide, vincristine, prednisolone, procarbazine, doxorubicin, bleomycin and dacarbazine for Hodgkin\'s lymphoma. Additionally, he developed skin hypersensitivity reaction secondary to procarbazine and prednisolone \[*dosages, routes, duration of treatment to reaction onset not stated; not all outcomes stated*\].

The boy, who was diagnosed with stage 4 Hodgkin\'s lymphoma, started receiving COPP regimen comprising cylophosphamide, vincristine, prednisolone and procarbazine. The first 2 courses of chemotherapy regimen were complicated by glucose intolerance and weight gain, which were attributed to the COPP regimen. Additionally, hypertension secondary to prednisolone was noted. At the day 6 of the chemotherapy, he developed maculopapular rash and widespread urticarial plaques over the whole body within a few hours following procarbazine administration. This skin hypersensitivity reaction was attributed to procarbazine and prednisolone.

The boy started receiving treatment with diphenhydramine and unspecified steroid therapy. His prednisolone therapy was continued. His hypersensitivity reaction improved within 48 hours. His procarbazine was discontinued, and he completed third chemotherapy course without procarbazine. Thereafter, his treatment was switched to ABVD regimen comprising doxorubicin \[Adriamycin\], vincristine, bleomycin and dacarbazine. On the day 10 of ABVD chemotherapy course (at day 25 of the last procarbazine dose), he was hospitalised due to tachypnoea and neutropenic fever. Laboratory test revealed lymphocytic count at 510 cell/mm ^3^. Chest radiograph revealed bilateral interstitial pneumonic infiltrations. He started receiving treatment with amikacin, clarithromycin, cotrimoxazole, meropenem and teicoplanin. His condition rapidly deteriorated in the next 12 hours, and he developed respiratory distress. He required mechanical ventilation and intubation. Chest radiographs showed a rapid progression of pneumonic infiltrates. Based on these findings, the diagnosis of ARDS was made. Further, he received amphotericin B. Viral secretions revealed positive respiratory syncytial virus infection. He was then treated with palivizumab and ribavirin. Cell cultures confirmed the presence of respiratory syncytial virus infection. The diagnosis of respiratory syncytial virus pneumonitis was made. He remained intubated for the 3 weeks and was discharged on hospitalisation day 28. After 3 months, pulmonary radiological findings were regressed completely.

**Author comment:** *\"Neutropenic fever and ARDS occurred at the 25th day of the last procarbazine dose however; he also received bleomycin. . .before this complication. Several factors might be related to this clinical condition including Hodgkin and/or chemotherapy\".\"\[S\]kin hypersensitivity developed after taking procarbazine. So procarbazine was thought that the responsible drug . . .These reactions can even occur in a \[prednisolone\]-induced immunosuppression phase.\"*
